MicroPort® Takes Part in 2019 Yangtze River Delta Health Summit

Shanghai, China – The 2019 Yangtze River Delta Health Summit (“Summit”) took place in Shanghai, China on May 11, 2019. The first edition of the Yangtze River Delta Health Summit was co-organized by the health commissions of Shanghai Municipality, Jiangsu Province, Zhejiang Province and Anhui Province, as well as Shanghai Jiao Tong University, under the guidance of Yangtze River Delta Regional Cooperation Office. The Summit, revolving around the theme of “Healthy Yangtze River Delta: Integration, Consensus, Action”, brought together over 400 delegates from the authorities, colleges and universities, hospitals, and companies of Shanghai, Jiangsu, Zhejiang and Anhui, who conducted thorough exchanges on how the integrated health development in the Yangtze River Delta should be promoted in an improved and expedited manner. Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”) Chief Operating Officer Ms. Glendy Wang attended the Summit and was a speaker in the session of “Healthy Yangtze River Delta, Synergized Development of Health Industry”.

Ms. Glendy Wang said that MicroPort® is constantly committed to bringing about a people-centric SuperCluster of emerging medical technologies and continuously following and coordinating its development with the integration of the Yangtze River Delta. Outside of Shanghai, MicroPort® currently operates production (R&D) facilities in Suzhou and Jiaxing. With regard to the promotion of the Yangtze River Delta’s integration in terms of high-end medical device industry, Ms. Glendy Wang suggested that firstly, the regional administrative barriers be dismantled to achieve mutual communications and recognitions of regulatory information across the Yangtze River Delta region and increase regulation efficiency; Secondly, the mutually complementary advantages within the Yangtze River Delta region be enhanced to build an industrial development mode featuring mutually supported industrial chains; Thirdly, comprehensive measures be taken in the Yangtze River Delta region to reduce companies’ operating costs to ensure their continued and high-quality development. The delegates from Shanghai Roche Pharmaceutical Co., Ltd., Sandoz (China) Pharmaceutical Co., Ltd. and Shanghai United Imaging Healthcare Co., Ltd. also presented their respective suggestions and proposals revolving around issues and bottlenecks in the Yangtze River Delta’s integrated development as well as improvement in business environment.

As a leading innovation-driven high-end medical device group from China and having grown up in the Yangtze River Delta, MicroPort® will follow the rationale of driven by innovation and stable business operation to fully coordinate the resource allocation in Shanghai, Suzhou and Jiaxing against the backdrop of the integrated development of the Yangtze River Delta. MicroPort® will also deepen the technological innovation system and industrial development mode, which feature market orientation and combination of production, education and researches, and continuously make additional contributions to further drive the integrated development of the Yangtze River Delta.